What is Acute Agitation and Aggression Treatment?
Acute agitation & aggressive treatments are defined as a collection of intensive-care-unit stay, resuscitation, and antibiotics to treat behavioural dyscontrol. Agitation is an excessive verbal and physical behaviour which can be intensify to aggression. This treatment is mainly arrived in different of medical and psychiatric conditions. It is particularly results in behavioural dyscontrol. Changing lifestyle and strong attention towards socialism and eager towards gaining social attentions, mental burden leads behavioural changes. Thus, to treat mental illness and manage mental health and to avoid acute agitation, different treatment are recommended. This treatments use of medication to calm agitated patients and lowers it’s ascertain dangerous behaviour. Certain therapy are used to treat and reduce aggressive behaviour in an adult. For instance, cognitive behavioural therapy (CBT) is used to treat acute agitation. Increasing awareness regarding mental sickness and availability of treatment is driving the demand for the market. Further, rising prevalence of psychiatric disorders demands for the treatments. However, less alertness regarding mental illness in certain emerging regions providing challenge to the market.
The market study is broken down and major geographies with country level break-up.
Bristol-Myers Squibb (United States), Johnson & Johnson (United States), Pfizer Inc. (United States), Hoffmann-La Roche Ltd. (United States), Astra Zeneca (United Kingdom), AbbVie Inc. (United States), Celgene (United States), Eli Lilly & Co (United States), Cadila Healthcare Limited (India), Dr. Reddy’s Laboratories Ltd. (India) and GlaxoSmithKline plc (United Kingdom) are some of the key players that are part of study coverage.
AdvanceMarketAnalytics has segmented the market of Global Acute Agitation and Aggression Treatment market by Type, Application and Region.
On the basis of geography, the market of Acute Agitation and Aggression Treatment has been segmented into . If we see Market by Therapy, the sub-segment i.e. Chemotherapy will boost the Acute Agitation and Aggression Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Route of Administration, the sub-segment i.e. Oral will boost the Acute Agitation and Aggression Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End Use, the sub-segment i.e. Hospitals & Clinics will boost the Acute Agitation and Aggression Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Disorder Type , the sub-segment i.e. Schizophrenia will boost the Acute Agitation and Aggression Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Antipsychotics will boost the Acute Agitation and Aggression Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
Market Leaders and their expansionary development strategiesIn February 2018, BullFrog AI, Inc, has established partnership with Lieber Institute for Brain Development. This is medical research institute working for mental disorders and its treatment. BullFrog AI, Inc is industry leader in AI and clinical data analytics services. With this partnership, company is able use its AI platform to analyse anti-psychotic drug responses. In addition, BullFrog AI is utilize their platform to analyse large multi-factorial clinical data of patients who received antipsychotic medication.
In June 2020, Sumitomo Dainippon Pharma has launched Atypical Antipsychotic Agent, LATUDA Tablets in Japan. It is an atypical antipsychotic agent for schizophrenia and bipolar depression. It has high tolerability and it is a first medication for the treatment of both diseases. With this new launch, company is able to provide generic version which have huge affordability for patients.
Regulation (EC) No 726/2004- Regarding the use of conventional antipsychotics to treat dementia. It is approved by (CHMP) The Committee for Medicinal Products for Human Use (CHMP) is the European Medicines Agency's (EMA) committee responsible for human medicines.
- Pharmaceutical Companies Conducting Massive R&D Activities for Development of the New Product Lines to Treat Advanced Psychiatric Disorders
- Growing Awareness Regarding Mental Illness
- Increasing Incidences of Psychiatric Disorders across the Globe
- Rising Attention towards Maintaining Mental Health with Proper Treatment
- Augmenting Government Spending’s On Psychiatric Research Institutes & Care Centers
- Rising Approvals for Antipsychotics Drugs to Treat Bipolar Disorders, Psychiatric Disorders and Mental Illness Has Created Growth Opportunities for Market
- Surge in Prescriptions of Anti-Psychotics
- Introduction of AI in the Treatments & Clinical Data Analysis
- Lack of Education Regarding Acute Agitation and Aggression & Mental Illness
- Side Effects Associated With Antipsychotics Drugs Expected To Hamper Its Demand
- Straighten Regulatory Norms
- Huge Requirement of Investments for Drug Developments
Key Target AudienceAcute Agitation and Aggression Treatment Manufacturers, Antipsychotics Manufacturers/Suppliers/Distributor, Raw Material Suppliers, Psychiatric Research Centers, New Entrants/Investors, Strategic Business Planners, Governments and Healthcare & Pharmaceutical Industry
About ApproachDuring this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand companys positioning regarding market value, volume and their market share for regional as well as global.
Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.
The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Customization available in this Study:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase